Savient begins Krysexxa shipment soon; ThermoGenesis inks distribution agreement;

 @FierceBiotech: CRO Charles River ($CRL) cuts 300 more jobs. Report | Follow @FierceBiotech

> Savient will begin shipping its gout drug, Krystexxa, on Nov. 30, 2010, with sales beginning Dec. 1. The company did not disclose the drug's price; it also released its third quarter financial results, which included a net loss of $59.4 million. Savient release

> Researchers may have found an early source of Parkinson's Disease: an energy crisis in the brain. Story

> ThermoGenesis has signed a distribution agreement covering China and Hong Kong for its products used to prepare cell concentrates, including stem cells, from bone marrow, at the point-of-care and in the laboratory. Report

> Nanoshells--hollow silica spheres covered with gold--were invented and are being tested in Houston. And they continue to surprise researchers with how effective they are. Researchers say they are killing breast cancer cells at a previously unreachable root level. Report

> Rules-Based Medicine has reached a major milestone with the commercial release of VeriPsych, a diagnostic test that looks at a complex array of 51 biomarkers to help physicians come up with a diagnosis of early-stage schizophrenia. But the test, the first blood-based tool of its type, has triggered a sharp debate among the experts about its accuracy and usefulness. Story

> The FDA is teaming up with drug developers, academics and others on a new program that urges regulators to agree on disease-specific biomarkers that can be used in the clinical trial process. And their goal is to find out earlier if they're on the right track or need to move on--cutting costs and shortening development cycles. Report

And Finally... The 26 vaccine-preventable diseases. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.